IDiyas

For the Inventor, By the Inventor

Duesseldorf, Germany

Dieter Petzinna

USPTO Granted Patents = 27

Average Co-Inventor Count = 7.2

ph-index = 6

Forward Citations = 376(Granted Patents)


Location History:

  • Duesseldorlf, DE (1990)
  • Wesel, DE (1988 - 1991)
  • Duesseldorf, DE (1988 - 1995)
  • Dusseldorf, DE (1995)
  • Du/ sseldorf, DE (1996)

Company Filing History:

goldMedal27 out of 12,157 
 
Bayer Aktiengesellschaft
 patents

Years Active: 1988-1996

Loading Chart...
27 patents (USPTO):Explore Patents
1. 5502057 - Polysubstituted pyridines useful for treating lipoproteinanaemia and (1996-03-26),
2. 5470982 - Disubstituted pyridines (1995-11-28),
3. 5401746 - Substituted pyridines heptenoic acid derivatives, useful for treating (1995-03-28),
4. 5183897 - Certain intermediate imino-substituted pyridines (1993-02-02),
5. 5177080 - Substituted pyridyl-dihydroxy-heptenoic acid and its salts (1993-01-05),
6. 5173495 - 7-[(2,6-dialkyl-4-furyl or (1992-12-22),
7. 5169857 - 7-(polysubstituted pyridyl)-hept-6-endates useful for treating (1992-12-08),
8. 5164506 - Substituted 2-pyridones and pyrid-2-thiones compounds (1992-11-17),
9. 5145959 - Substituted pyrido (2,3-d) pyrimidines as intermediates (1992-09-08),
10. 5145857 - HMG-COA reductase-inhibiting substituted amino-pyridines (1992-09-08),
11. 5075311 - HMG-CoA reductase inhibiting substituted pryido (2,3-d) pyrimidines (1991-12-24),
12. 5064841 - HMG-COA reductase-inhibiting imino-substituted pyridines (1991-11-12),
13. 5034399 - Substituted 1,8-naphthyridines and their use in medicaments (1991-07-23),
14. 5032602 - Inhibiting HMG-CoA reductase with novel substituted 2-pyridones and (1991-07-16),
15. 5032590 - Substituted hydroxylamines (1991-07-16),

Title: Innovator Dieter Petzinna: Pioneering Solutions in Lipoprotein Metabolism

Introduction: Dieter Petzinna, based in Düsseldorf, Germany, is a prominent inventor known for his significant contributions to the field of medicinal chemistry. With an impressive portfolio of 27 patents, Petzinna has been instrumental in developing novel compounds that target various metabolic conditions, particularly those related to lipoprotein abnormalities.

Latest Patents: Among his latest innovative contributions, Dieter Petzinna has developed polysubstituted pyridines that are useful for treating lipoproteinanaemia. Additionally, he has focused on disubstituted pyridines designed for the treatment of lipoproteinaemia and arteriosclerosis. These compounds, characterized by the formula ##STR1## where R¹ is optionally substituted aryl or heteroaryl, reflect his commitment to advancing therapeutic options for patients suffering from cardiovascular diseases.

Career Highlights: Throughout his career, Dieter Petzinna has worked with Bayer Aktiengesellschaft, a leading global pharmaceutical company. His role at Bayer has allowed him to conduct groundbreaking research and implement innovative solutions that have the potential to transform treatment methodologies in cardiovascular health.

Collaborations: Collaboration is vital in the innovation process, and Dieter Petzinna has worked alongside esteemed colleagues such as Hilmar Bischoff and Rolf Angerbauer. Their joint efforts have undoubtedly contributed to the advancement of research and the successful development of new therapeutic agents.

Conclusion: Dieter Petzinna's dedication to innovation in the pharmaceutical industry is evident through his numerous patents and significant research contributions. His work in developing new treatments for lipoprotein metabolism highlights the importance of continued research and collaboration in the quest for effective medical solutions, further cementing his status as a key player in the field of medicinal chemistry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…